Latest news with #chronicrhinitis
Yahoo
30-06-2025
- Health
- Yahoo
Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®
Effective September 15, CPT 31242 is no longer considered experimental, clearing an important barrier for ENT physicians treating chronic rhinitis. GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that Cigna Healthcare will provide coverage for NEUROMARK treatment of the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15th, 2025. This policy update is an important step in improving patient access to innovative treatment options for chronic rhinitis and reflects growing payer recognition of the procedure's therapeutic value. This update removes a key barrier that previously limited the ability for ENT physicians to treat Cigna patients using posterior nasal nerve ablation. "This is a significant moment for ENT providers and patients alike," said Brian Shields, CEO of Neurent Medical. "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system" The NEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt the parasympathetic nerve signals, addressing key symptoms of Chronic Rhinitis such as persistent nasal congestion and rhinorrhea (runny nose). "Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions" said Dr. Peter Manes, Associate Professor at Yale School of Medicine. "This policy update is significant and helps otolaryngologists offer a modern, evidence-supported treatment with fewer administrative hurdles. The large and growing evidence base makes it more difficult for patients to be denied access to such technologies." Key Points for Providers: CPT 31242 is no longer classified as investigational by Cigna Precertification is not required under the updated policy (always confirm benefits per individual plan) The policy supports more streamlined access to NEUROMARK for eligible patients To view Cigna's updated medical policy, visit:CIGNA Policy LINK For more information about NEUROMARK, visit or contact your local Neurent Medical Sales Representative. About Neurent Medical Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit PAM225r01 View original content to download multimedia: SOURCE Neurent Medical
Associated Press
27-06-2025
- Health
- Associated Press
Cigna Enables Coverage for RhinAer®
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 27, 2025-- Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer ® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis. Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna's policy update highlights the growing recognition of RhinAer's clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management. 'Cigna's decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients,' said Matt Brokaw, CEO of Aerin Medical. 'Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition's burden.' 'Chronic rhinitis takes a substantial toll on patients and Cigna's decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients,' said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. 'With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna's decision supports the adoption of a therapy that elevates the standard of care for patients.' Information for Providers: The codes 31242 - Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve and 31243 - Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve have been removed from experimental / investigational status and will not require precertification. For more information about Cigna's updated medical policy for RhinAer (CPT 31242), visit: About RhinAer Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer ® for nasal airway obstruction and RhinAer ® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube. View source version on CONTACT: Media Contact: Michael Fanucchi Aerin Medical [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH INSURANCE OTHER HEALTH HEALTH INSURANCE GENERAL HEALTH PHARMACEUTICAL SOURCE: Aerin Medical Inc. Copyright Business Wire 2025. PUB: 06/27/2025 11:00 AM/DISC: 06/27/2025 11:01 AM
